In a statement, Chip Davis, president and CEO of GPhA offers support of a study published in JAMA identifying opportunity for drug savings.
Chip Davis, president and CEO of the Generic Pharmaceutical Association (GPhA) offered praise of a study published on May 9, 2016 in the Journal of the American Medical Association (JAMA) Internal Medicine. The new study revealed that from 2010–2012, in the United States, more than $73 billion was spent on brand drugs when generic alternatives were available. Approximately 33% of that cost came from patients paying out-of-pocket for drugs, according to the study. Additionally the study says that less than optimal therapeutic substitution remains a missed opportunity for patient and health system savings.
In a May 12, 2016 statement, Davis wrote that this study might offer patients new opportunities for generic savings. In 2014, Davis wrote, generics saved the US healthcare system $254 billion, according to the “Generic Drug Savings in the US” report by IMS Institute for Healthcare Informatics. “Still, there is more that can be done to put unrealized savings back into the health system,” Davis wrote.
Davis says that to increase the use and prescription of generics, Congress and others can pursue policy solutions. These policy solutions, Davis suggested, may include addressing FDA’s generic-drug application backlog, increasing the use of generics among the low-income Medicare population, the passing of the FAST Generics Act, ensuring biosimilars are safe and effective alternatives to biologics, and repealing Section 602 of the Bipartisan Budget Act of 2015.
Source: GPhA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.